Abstract
The article discusses and supports alternatives to improve the Russian regulatory system of sales allowances to pricing on pharmaceuticals , included in the Vital and Essential Drugs List; which were developed by means of analytical research in order to encourage sales of cheaper pharmaceuticals and price decreases on expensive ones. In addition, based on the world practice, possible ways of the state regulation of pharmaceutical maximum margins are highlighted and suggested the most appropriate for domestic pharmaceuticals distribution system.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
